| Literature DB >> 20473312 |
Maria Kleppe1, Idoya Lahortiga, Tiama El Chaar, Kim De Keersmaecker, Nicole Mentens, Carlos Graux, Katrien Van Roosbroeck, Adolfo A Ferrando, Anton W Langerak, Jules P P Meijerink, François Sigaux, Torsten Haferlach, Iwona Wlodarska, Peter Vandenberghe, Jean Soulier, Jan Cools.
Abstract
PTPN2 (protein tyrosine phosphatase non-receptor type 2, also known as TC-PTP) is a cytosolic tyrosine phosphatase that functions as a negative regulator of a variety of tyrosine kinases and other signaling proteins. In agreement with its role in the regulation of the immune system, PTPN2 was identified as a susceptibility locus for autoimmune diseases. In this work, we describe the identification of focal deletions of PTPN2 in human T-cell acute lymphoblastic leukemia (T-ALL). Deletion of PTPN2 was specifically found in T-ALLs with aberrant expression of the TLX1 transcription factor oncogene, including four cases also expressing the NUP214-ABL1 tyrosine kinase. Knockdown of PTPN2 increased the proliferation and cytokine sensitivity of T-ALL cells. In addition, PTPN2 was identified as a negative regulator of NUP214-ABL1 kinase activity. Our study provides genetic and functional evidence for a tumor suppressor role of PTPN2 and suggests that expression of PTPN2 may modulate response to treatment.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20473312 PMCID: PMC2957655 DOI: 10.1038/ng.587
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330